Company Description
Squarex Pharmaceutical is a late-clinical-stage pharmaceutical company developing a drug that is intended to improve immune function to reduce severity and incidence of infectious disease with an initial focus on oral herpes.
Our drug SQX770 has completed a Phase 1 and a Phase 2 placebo-controlled clinical trial and showed a statistically significant effect in non-primary endpoints in both trials of delaying time to next herpes labialis or oral herpes (cold sore) outbreak and reducing the number of outbreaks of cold sores (herpes labialis) after a single dose in persons with frequent outbreaks.
The drug has been well tolerated in clinical trials with no serious adverse events. None of the data obtained in clinical trials to date would be accepted by the FDA as indicative of efficacy.
The FDA will base any approval on the results of Phase 3 clinical trials, which have not been initiated.
The SQX770 drug is topically applied on a patient’s arm, not the face or lip or a lesion. In the Phase 3 trials and commercially, we plan to dose patients once every three months.
| Country | United States |
| Founded | 2012 |
| Industry | Health Care |
| Sector | Pharmaceuticals |
| Employees | 1 |
| CEO | Hugh McTavish |
Contact Details
Address: 1000 Westgate Drive, Suite 1010 Saint Paul, MN 55114 United States | |
| Phone | 651-207-8270 |
| Website | healthcaretriangle.com |
Stock Details
| Ticker Symbol | SQRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001864607 |
| Employer ID | 45-5576357 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hugh McTavish, Ph.D. | Chairman, Chief Executive Officer, President and Chief Scientist |
| Kwang Lee | Interim Chief Financial Officer |
| Arkadiusz Dudek, M.D. | Director |
| Wayne I. Danson | Director |
| Michael Myers, Ph.D. | Director |
| Mark W. Schwartz, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2023 | RW | Filing |
| Apr 4, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 17, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 2, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 22, 2022 | D | Notice of Exempt Offering of Securities |
| Oct 14, 2022 | DRS | [Cover] Draft Registration Statement |
| Oct 22, 2021 | C/A | Filing |
| Sep 14, 2021 | C | Filing |